by embracemarketing | Oct 23, 2019 | non BLOG
An influx of new treatments including cancer immunotherapies, CAR-T and other novel Mechanism of Actions have and continue to enter the market. This rapid influx has led to confusion across the positioning of key brands for many oncologists. Adelphi has addressed this...
by embracemarketing | Oct 23, 2019 | non BLOG
The oncology landscape has changed dramatically in recent years with an influx of new treatments including immunotherapies, CAR-T and other novel MOAs entering the market. The influx of change has meant Oncologists are confused and unable to clearly distinguish across...
by embracemarketing | Oct 11, 2019 | non BLOG, Uncategorized
NICE has used Adelphi’s research project as a pilot to inform guidance to set standards around patient preference study design. Adelphi’s client wanted a patient preference study that would stand up to NICE scrutiny for their HTA submission. Together with our client,...
by embracemarketing | Oct 11, 2019 | non BLOG, Uncategorized
Adelphi’s work with Rethink Mental Illness has helped bring about significant changes to the Mental Health Act. Our work involved investigating the level of choice and involvement people with severe mental illness have when detained under the current Mental...
Recent Comments